Discover
MRUS
Merus N.V.
90.00
2 x 69.74
2 x 124.07
bid
ask
+
90.00
0.00%
2 @ 07:00 PM
89.00 -1.00 (1.11%)
| Ytd | 0.00% | |
| 1y | 112.77% |
day range
52 week range
| Open | Prev Close | Low | High | Mkt Cap | N/A | ||||
| Vol | 0.00 | Avg Vol | 0.00 | EPS | N/A | P/E | N/A | Forward P/E | -17.65 |
| Beta | 1.06 | Short Ratio | 0.59 | Inst. Own | 92.80% | Dividend | N/A | Div Yield | N/A |
| Ex Div Date | N/A | Earning | N/A | 50-d Avg | N/A | 200-d Avg | N/A | 1yr Est | 97.00 |
Earning
| Date | For | Estimate | Reported | Surprise | surprise % |
|---|---|---|---|---|---|
| 2025-10-31 | 2025-09 | 0 | N/A | N/A | N/A |
| 2025-08-05 | 2025-06 | 0 | N/A | N/A | N/A |
| 2025-05-07 | 2025-03 | 0 | N/A | N/A | N/A |
| 2025-02-27 | 2024-12 | 0 | N/A | N/A | N/A |
| 2024-10-31 | 2024-09 | 0 | N/A | N/A | N/A |
| 2024-08-01 | 2024-06 | 0 | N/A | N/A | N/A |
Upgrade / Downgrade
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| 2025-10-06 | Leerink Partners | Downgrade | Outperform | Market Perform |
| 2025-09-30 | Guggenheim | Downgrade | Buy | Neutral |
| 2025-09-30 | Canaccord Genuity | Downgrade | Buy | Hold |
| 2025-09-30 | Wells Fargo | Downgrade | Overweight | Equal-Weight |
| 2025-09-30 | UBS | Downgrade | Buy | Neutral |
| 2025-09-30 | LifeSci Capital | Downgrade | Outperform | Market Perform |
Profile
Merus N.V., a clinical-stage immuno-oncology company, engages in the development of antibody therapeutics in the Netherlands. Its bispecific antibody candidate pipeline includes BIZENGRI for the treatment of patients with pancreatic adenocarcinoma or non-small cell lung cancer (NSCLC) and non Neuregulin 1. The company is also developing MCLA-158 for the treatment of solid tumors; MCLA-129 for the treatment of patients with lungs and other solid tumors; ONO-4685 to treat relapsed/refractory T cell lymphoma; and INCA33890 for advanced solid tumors. In addition, it has collaboration agreement with Eli Lilly and Company, Ono Pharmaceutical Co., Ltd., and Betta Pharmaceuticals Co. Ltd. The company was incorporated in 2003 and is headquartered in Utrecht, the Netherlands. As of December 11, 2025, Merus N.V. operates as a subsidiary of Genmab A/S.
Insider Holder
| Date | Name | Relation | Quantity | Description |
|---|---|---|---|---|
| 2021-07-01 | BAKKER LEX B H | Officer | 15.67K | Conversion of Exercise of derivative security |
| 2021-07-01 | BVF PARTNERS L P | Beneficial Owner of more than 10% of a Class of Security | 0.00 | Sale |
| 2021-10-07 | BVF PARTNERS L.P. | Beneficial Owner of more than 10% of a Class of Security | 0.00 | Sale |
| 2021-08-11 | DE KRUIF JOHN | Chief Technology Officer | 15.28K | Sale |
| 2025-12-25 | GENMAB AS | Beneficial Owner of more than 10% of a Class of Security | 0.00 | Purchase |
| 2023-04-13 | IWICKI MARK T. | Director | 73.58K | Conversion of Exercise of derivative security |
Institution Ownership
| Report Date | Organization | Position | Value | Percentage |
|---|---|---|---|---|
| 2025-09-29 | Paradigm Biocapital Advisors LP | 4.37M | 393.64M | 5.77% |
| 2025-09-29 | Avoro Capital Advisors LLC | 3.54M | 318.83M | 4.67% |
| 2025-09-29 | Commodore Capital Lp | 3.53M | 317.25M | 4.65% |
| 2025-09-29 | Deerfield Management Company, L.P | 3.05M | 274.22M | 4.02% |
| 2025-09-29 | HBK Investments L P | 2.85M | 256.50M | 3.76% |
| 2025-09-29 | FMR, LLC | 2.81M | 252.98M | 3.71% |
Fund Ownership
| Report Date | Organization | Position | Value | Percentage |
|---|---|---|---|---|
| 2025-10-30 | Federated Hermes Equity Funds-Federated Hermes Kaufmann Small Cap Fund | 640.00K | 57.60M | 0.84% |
| 2025-09-29 | Fidelity Rutland Square TRT II-Strategic Advisers U.S. Total Stock Fd. | 620.89K | 55.88M | 0.82% |
| 2025-10-30 | Federated Hermes Equity Funds-Federated Hermes Kaufmann Fund | 593.00K | 53.37M | 0.78% |
| 2025-10-30 | Columbia Funds Series Trust I-Columbia Cornerstone Growth Fund | 509.00K | 45.81M | 0.67% |
| 2025-09-29 | SmallCap World Fund Inc | 491.24K | 44.21M | 0.65% |
| 2025-10-30 | iShares Trust-iShares Biotechnology ETF | 412.87K | 37.16M | 0.54% |